Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2165)	8/8/2003 4:28:23 PM
From: scaram(o)uche	Respond to of 2243

Oh, yeah, accountability. I forgot. Conveniently. HCV371 for VPHM crashed. No moon-shot, but (taking any old excuse to sound like it didn't hurt)........ T/FIF-like...... on this end of that major setback, I believe that we're probably still up from where the discussion initiated. Thanks for the COR update. Have a good weekend! Rick

To: Icebrg who wrote (2165)	8/19/2003 4:47:21 PM
From: Icebrg	Read Replies (1) \| Respond to of 2243

>> Cortex Pharmaceuticals COR >> Some words from DARPA on their research on Ampakines. DARPA’s Bio-Revolution thrust has four broad elements: . . . Let me give you some example of our work here . . . Our Continuous Assisted Performance (CAP) program is investigating ways to prevent fatigue and enable soldiers to stay awake, alert, and effective for up to 7 consecutive days without suffering any deleterious mental or physical effects and without using any of the current generation of stimulants. In a recent series of studies, a new class of drugs, ampakines, has been identified that appears to be effective in eliminating the negative effects of sleep deprivation. Monkeys deprived of sleep for 30 hours showed complete recovery from cognitive, brain electrical signal, and brain metabolism defects when given the drug. We are aggressively pursuing development of these drugs as replacements for current stimulants. defense.gov